{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:48:14Z","timestamp":1768070894634,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH"},{"name":"CTSA"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.urolonc.2017.07.024","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T21:16:04Z","timestamp":1502226964000},"page":"670.e7-670.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Quadruple immunotherapy of Bacillus Calmette-Gu\u00e9rin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non\u2013muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Ryan L.","family":"Steinberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G.","family":"Nepple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyla N.","family":"Velaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.07.024_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib3","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib5","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","article-title":"Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value","volume":"155","author":"de Reijke","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.urolonc.2017.07.024_bib8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","article-title":"Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guerin immunotherapy","volume":"14","author":"Shintani","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2006.05.003","article-title":"Aging and innate immunity","volume":"24","author":"Solana","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.urolonc.2017.07.024_bib10","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0022-5347(17)37916-8","article-title":"Bacillus Calmette-Guerin and interleukin-2 for treatment of superficial bladder cancer","volume":"146","author":"Cockett","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0022-5347(17)43958-9","article-title":"Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report","volume":"137","author":"Merguerian","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib14","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib15","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.4049\/jimmunol.179.12.8418","article-title":"Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs","volume":"179","author":"Ryan","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2017.07.024_bib18","unstructured":"Crawford J, Becker PS, Armitage J, Blayney DW, Cataland S. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Myeloid Growth Factors. Version 1, 2015. Available at: NCCN.org. [accessed October 10, 2015]."},{"key":"10.1016\/j.urolonc.2017.07.024_bib19","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1442-2042.2012.03089.x","article-title":"Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer","volume":"19","author":"Lightfoot","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1442-2042.2002.00415.x","article-title":"Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guerin (BCG): a role of BCG internalization into tumor cells","volume":"9","author":"Ikeda","year":"2002","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib21","first-page":"4286","article-title":"Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells","volume":"52","author":"Lattime","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2017.07.024_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/cbr.1993.8.223","article-title":"Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study","volume":"8","author":"Gomella","year":"1993","journal-title":"Cancer Biother"},{"key":"10.1016\/j.urolonc.2017.07.024_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-5347(01)63548-1","article-title":"Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients","volume":"159","author":"Den Otter","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-5347(17)39547-2","article-title":"A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder","volume":"144","author":"Glashan","year":"1990","journal-title":"J Urol"},{"issue":"6B","key":"10.1016\/j.urolonc.2017.07.024_bib25","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/j.1582-4934.2009.00818.x","article-title":"A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF","volume":"14","author":"Hu","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.urolonc.2017.07.024_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options for BCG failures","volume":"24","author":"O'Donnell","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib30","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib31","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.07.024_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.07.024_bib33","first-page":"257","article-title":"BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder","volume":"67","author":"Bercovich","year":"1995","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.urolonc.2017.07.024_bib34","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J Immunol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917303861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917303861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:12:40Z","timestamp":1761041560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917303861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1078143917303861"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.024","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quadruple immunotherapy of Bacillus Calmette-Gu\u00e9rin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non\u2013muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}